In early-stage CRC, SLC9A2 can inhibit tumor metastatic progression, while in advanced stages, it serves as an immunosensitizing molecule that reverses resistance to immunotherapy in liver metastasis. The gene discussed is SLC9A2; the disease is neoplasm.